Home |  Elder Rights |  Health |  Pension Watch |  Rural Aging |  Armed Conflict |  Aging Watch at the UN  

  SEARCH SUBSCRIBE  
 

Mission  |  Contact Us  |  Internships  |    

        

 

 

 

 

 

 

 

 




Top Ten Drug Interactions Most Dangerous to Seniors in Long-Term Care

Senior Journal

December 14, 2004


The initiative is called the Multidisciplinary Medication Management Project. The goal of the project is to foster collaboration among consultant pharmacists, medical directors, attending physicians, and other health professionals in long-term care to improve the prescribing, monitoring, and use of medications in long-term care residents.

A 1997 study published in Archives of Internal Medicine, found that 35 percent of ambulatory older adults have had an adverse event due to drug interaction and most of them required medical care as a result. The incidence was even higher in nursing homes, where two-thirds of residents experienced such events over a four-year period. A more recent study published in March 2003 in the Journal of the American Medical Association found that 27.6 percent of adverse drug events in older people were preventable.

Another reason for these increased adverse events is how drugs affect people may change as they age. "As we age, we have more subcutaneous fat, less lean body mass, less total body water; all those things conspire together to lead to increased drug toxicity and overdose," said Dr. Donna M. Fick, a geriatric clinical nurse specialist and associate professor of medicine at the Medical College of Georgia in Augusta .

The M3 Project Advisory Committee undertook to identify ten drug interactions that are commonly regarded as important, and involve medications that are commonly used in older adults in long-term care settings. Each of these drug interactions has the potential to cause significant harm if not managed appropriately.

The committee believes that if health professionals in long-term care can focus on preventing or managing these ten drug interactions, a significant impact can be made on improving care for these older adults.

List of Top Ten Drug Interactions in Long-Term Care


Medications chosen for the Top Ten list were based on their frequency of use in older adults in the long-term care setting, and on the potential for adverse consequences if used together. Due to individual variability, not every older adult who takes these medications together will experience an adverse reaction. However, these combinations have the potential to produce harmful effects.

The purpose of this Top Ten list is to alert the interdisciplinary team to the possibility that a negative interaction may occur, so that steps may be taken to choose alternative medications, adjust doses, monitor the patient carefully, or take other such actions as may be appropriate.

Here they are:

Warfarin

NSAIDs

Coumadin, warfarin

Aleve, Anaprox, Anaprox DS, Ansaid, Arthrotec, Cataflam, Clinoril, Daypro, diclofenac, diclofenac/mistoprostrol, diflunisal, Dolobid, etodolac, Feldene, flurbiprofen, ibuprofen, Indocin, Indocin SR, indomethacin, ketoprofen, ketorolac, Lodine, Lodine XL, mefenamic acid, meloxican, Mobic, Motrin, nabumetone, Naprelan, Naprosyn, naproxen, Orudis, Oruvail, oxaprozin, piroxicam, Ponsel, Relafen, sulindac, Tolectin, Tolectin DS, tolmetin, Toradol, Voltaren, Voltaren XR

Impact: Potential for serious gastrointestinal bleeding

Mechanism of interaction
: NSAIDs increase gastric irritation and erosion of the protective lining of the stomach, assisting in the formation of a GI bleed. Additionally, NSAIDs decrease the cohesive properties of platelets necessary in clot formation.

Prevention:
Avoid concomitant use of an NSAID with warfarin. Identify reason for NSAID therapy. If anti-pyretic effects are desired, then consider acetaminophen. Acetaminophen in doses less than 2g/day on a short-term basis does not appear to affect the INR. Long-term use of acetaminophen for anti-pyretic and analgesic effects is controversial. If anti-inflammatory effects are necessary, then consider cyclooxygenase-2 (COX-2) inhibitor therapy. The minimization of gastric irritation with these agents combined with the lack of anti-platelet action, support the cautious use of COX-2 inhibitors in anticoagulation patients. There are some case reports discussing the elevation of INRs with COX-2 inhibitors. If analgesic effects are desired, caution should also be exhibited with the use of tramadol; there are a few case reports describing an elevation of the INR with concomitant administration of tramadol with warfarin.

Management:
Prothrombin time and INR should be monitored every week with co-administration of warfarin with an NSAID. Signs and symptoms of an active bleed should be monitored with particular attention to the appearance and patterns of bruises. Signs of an active bleed include: coughing up blood in the form of coffee grinds (hemoptysis), gum bleeding, nose bleeds, cola- or tea-colored urine (hematuria), or black, tarry stools (hemoccult positive).

Warfarin

Sulfa Drugs

Coumadin, warfarin

Bactrim DS, Bactrim SS, Cotrim DS, Cotrim SS, erythromycin/sulfisoxazole, Gantanol, Gantrisin, Pediazole, Septra DS, Sulfatrim, sulfamethizole, sulfamethoxazole, sulfisoxazole, Thiosulfil Forte, trimethoprim/sulfamethoxazole

Impact: Increased effects of warfarin, with potential for bleeding

Mechanism of interaction:
Currently, the mechanism for interaction with sulfa drugs is unknown; however, clinicians hypothesize that warfarin's activity is prolonged due to a decreased production of vitamin K by intestinal flora affected by systemic antibiotic administration.

Prevention:
Avoid concomitant use of a sulfa drug with warfarin, particularly sulfamethoxazole-trimethoprim. Identify microbial pathogen prior to initiation of antibiotic therapy. Consider culture sensitivity screening as research indicates cautious use of any antibiotic with warfarin. If use of a sulfa drug is imperative, then reduce warfarin dose by 50% during antibiotic administration and for one week following completion of the antibiotic. If sulfamethoxazole-trimethoprim therapy is required, then monitor INR every other day for elevating trends.

Management: Prothrombin time and INR should be monitored every week during co-administration of warfarin with a sulfa drug. Signs and symptoms of an active bleed should be monitored daily with particular attention to the appearance and patterns of bruises. Signs of an active bleed include: coughing up blood in the form of coffee grinds (hemoptysis), gum bleeding, nose bleeds, cola- or tea-colored urine (hematuria), and black, tarry stools (hemoccult positive).

Warfarin

Macrolides

Coumadin, warfarin

azithromycin, Biaxin, clarithromycin, Dynabac, dirithromycin, E-Mycin, erythromycin base, EES, erythromycin ethyl succinate, Ery-Tab, Eryc, EryPed, Erythrocin, erythromycin stearate, Ilosone, erythromycin estolate, Pediazole, erythromycin/sulfisoxazole, Tao, troleandomycin, Zithromax

Impact: Increased effects of warfarin, with potential for bleeding

Mechanism of interaction:
Erythromycin inhibits the metabolism and subsequent clearance of warfarin from the body. The activity of warfarin may also be prolonged due to alterations in the intestinal flora and its production of vitamin K for clotting factor production.

Prevention:
The interaction between warfarin and macrolide antibiotics is highly probable and often delayed. Concomitant use of a macrolide with warfarin should be avoided; switch to an alternative antibiotic. Microbial pathogen identification prior to antibiotic initiation will decrease the prevalence of unnecessary drug interaction risk. Consider culture sensitivity screening as research indicates cautious use of any antibiotic with warfarin.

Management:
If use of a macrolide is imperative, then monitor INR every other day and adjust warfarin dosing as necessary. Signs and symptoms of an active bleed should be monitored daily with particular attention to the appearance and patterns of bruises. Signs of an active bleed include: coughing up blood in the form of coffee grinds (hemoptysis), gum bleeding, nose bleeds, cola- or tea-colored urine (hematuria), and black, tarry stools (hemoccult positive).

Note: Although caution may be warranted when using warfarin with all quinolones, Drug Interaction Facts notes that problems have been documented especially with ciprofloxacin, ofloxacin, and norfloxacin. In addition, the M3 Project committee has received a number of reports of INR elevations with levofloxacin.

Warfarin

Quinolones

Coumadin, warfarin

alatrofloxacin, Avelox, Cipro, ciprofloxacin, enoxacin, Floxin, gatifloxacin, Levaquin, levofloxacin, lomefloxacin, Maxaquin, moxifloxacin, Noroxin, norfloxacin, ofloxacin, Penetrex, sparfloxacin, Tequin, trovafloxacin, Trovan, Trovan IV, Zagam

Impact: Increased effects of warfarin, with potential for bleeding

Mechanism of interaction:
The exact mechanism for the warfarin-quinolone drug interaction is unknown. Reduction of intestinal flora responsible for vitamin K production by antibiotics is probable as well as decreased metabolism and clearance of warfarin.

Prevention:
Culture and identify microbial pathogen prior to initiation of antibiotic therapy. Consider culture sensitivity screening. The metabolism of warfarin may be delayed in patients administered enoxacin, ciprofloxacin, norfloxacin, or ofloxacin; thus, quinolone selection should focus on one of the newer agents that has not demonstrated significant impairment of warfarin metabolism. Additionally, microbial pathogen identification and sensitivity prior to antibiotic initiation will decrease the prevalence of unnecessary drug interaction risk.

Management:
Prothrombin time and INR should be monitored during co-administration of warfarin with a quinolone. If use of ciprofloxacin is imperative, then monitor INR every other day and adjust warfarin dose as necessary. Signs and symptoms of an active bleed should be monitored daily with particular attention to the appearance and patterns of bruises.

Signs of an active bleed include: coughing up blood in the form of coffee grinds (hemoptysis), gum bleeding, nose bleeds, cola- or tea-colored urine (hematuria), and black, tarry stools (hemoccult positive).

Warfarin

Phenytoin

Coumadin, warfarin

Dilantin, phenytoin

Impact: Increased effects of warfarin and/or phenytoin

Mechanism of interaction:
Currently unknown, but one theory suggests a genetic basis involving liver metabolism of warfarin and phenytoin.

Prevention:
Obtain baseline phenytoin levels prior to initiation of warfarin. Monitor INR during co-administration. Target INR should be towards the lower end of the therapeutic range.


Management:
Prothrombin time, INR , and phenytoin levels should be monitored during co-administration. Signs and symptoms of an active bleed should be monitored daily with particular attention to the appearance and patterns of bruises. Signs of an active bleed include: coughing up blood in the form of coffee grinds (hemoptysis), gum bleeding, nose bleeds, cola- or tea-colored urine (hematuria), and black, tarry stools (hemoccult positive).

ACE Inhibitors

Potassium Supplements

Accupril, Aceon, Altace, benazepril, Capoten, captopril, enalapril, fosinopril, lisinopril, Lotensin, Mavik, moexipril, Monopril, perindopril, Prinivil, quinapril, ramipril, trandolapril, Univasc, Vasotec, Zestril

K+ Care ET, Kaon, K-dur, Klor-Con, K-Phos, Micro-K, potassium acetate, potassium acid phosphate, potassium bicarbonate, potassium chloride, potassium citrate, potassium gluconate, Urocit-K

Impact: Elevated serum potassium

Mechanism of interaction:
Inhibition of ACE results in decreased aldosterone production and potentially decreased potassium excretion.

Prevention:
Draw potassium level prior to initiation of ACE-inhibitor in a patient.

Management:
Potassium levels greater than 5 should be monitored carefully due to risk of severe hyperkalemia and EKG changes. Watch renal function (BUN, SCr) also. Adjust potassium supplementation if levels increase.

ACE Inhibitors

Spironolactone

Accupril, Aceon, Altace, benazepril, Capoten, captopril, enalapril, fosinopril, lisinopril, Lotensin, Mavik, moexipril, Monopril, perindopril, Prinivil, quinapril, ramipril, trandolapril, Univasc, Vasotec, Zestril

Aldactone, spironolactone

Impact: Elevated serum potassium levels

Mechanism of interaction:
Unknown, possibly an additive effect.

Prevention:
Draw potassium level prior to initiation of spironolactone in a patient.

Management:
Potassium levels greater than 5 should be monitored carefully due to risk of severe hyperkalemia and EKG changes. Watch renal function (BUN, SCr) also. Avoid potassium supplements in patients taking this combination of medications, unless the need is documented and the patient is monitored closely for hyperkalemia.

Digoxin

Amiodarone

digoxin, Lanoxin

amiodarone, Cordarone

Impact: Digoxin toxicity

Mechanism of interaction:
Multiple theories exist, but actual mechanism is unknown. Amiodarone may decrease the clearance of digoxin, resulting in prolonged digoxin activity. There may also be an additive effect on the sinus node of the heart.

Prevention:
Obtain digoxin level prior to initiation of amiodarone therapy. Then, decrease dose of digoxin by 50% and monitor digoxin levels once weekly for several weeks.

Management:
Maintain digoxin level between 1-2. Monitor for signs and symptoms of digoxin toxicity (abdominal pain, anorexia, bizarre mental symptoms in the elderly, blurred vision, bradycardia, confusion, delirium, depression, diarrhea, disorientation, drowsiness, fatigue, hallucinations, halos around lights, reduction in visual acuity, mydriasis nausea, neuralgia, nightmares, personality changes, photophobia, restlessness, vertigo, vomiting, and weakness).

Digoxin

Verapamil

digoxin, Lanoxin

Calan, Calan SR, Covera-HS, Isoptin, Isoptin SR, verapamil, Verelan

Impact: Digoxin toxicity

Mechanism of interaction:
Synergistic effect of slowing impulse conduction and muscle contractility, leading to bradycardia and possible heart block.

Prevention:
Monitor heart rate and EKG-PR interval. Evaluate selection of verapamil and digoxin. If patient has CHF, note that verapamil has no proven benefit in reducing mortality or morbidity; furthermore, digoxin offers no additional benefit in mortality, but does improve symptomatology.

Management:
Monitor heart rate and EKG-PR interval. Monitor for signs and symptoms of digoxin toxicity (abdominal pain, anorexia, bizarre mental symptoms in the elderly, blurred vision, bradycardia, confusion, delirium, depression, diarrhea, disorientation, drowsiness, fatigue, hallucinations, halos around lights, visual acuity, mydriasis, nausea, neuralgia, nightmares, personality changes, photophobia, restlessness, vertigo, vomiting, and weakness).

Note: Although caution may be warranted when using theophylline with all quinolones, Drug Interaction Facts notes that problems have been documented especially with ciprofloxacin, enoxacin, and norfloxacin.

Theophylline

Quinolones

aminophylline, Choledyl SA, oxtriphylline, Phyllocontin, Slo-Bid, Slo-Phyllin, Slo-Phyllin 125, Theo-24, Theo-Dur, Theolair, theophylline, Uniphyl, Uniphyl CR

alatrofloxacin, Avelox, Cipro, ciprofloxacin, enoxacin, Floxin, gatifloxacin, Levaquin, levofloxacin, lomefloxacin, Maxaquin, moxifloxacin, Noroxin, norfloxacin, ofloxacin, Penetrex, sparfloxacin, Tequin, trovafloxacin, Trovan, Trovan IV, Zagam

Impact: Theophylline toxicity

Mechanism of interaction:
Inhibition of hepatic metabolism of theophylline by the quinolones.

Prevention:
Obtain theophylline level prior to initiation of a quinolone. Of the quinolones, enoxacin and ciprofloxacin reduce theophylline clearance by 30-84%. Consider switching to gatifloxacin, levofloxacin, moxifloxacin, or trovafloxacin; these agents appear not to inhibit theophylline metabolism.

Management:
Monitor theophylline levels. Maintain level within targeted range of 5-15mcg/mL; however, theophylline toxicity may result even when the level is within the targeted range. Signs and symptoms of theophylline toxicity include seizures, nausea, and vomiting.

Content developed by: Karen E. Brown, PharmD

 

 


Copyright © Global Action on Aging
Terms of Use  |  Privacy Policy  |  Contact Us